Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

International Journal of Endocrinology
Volume 2016, Article ID 1615735, 11 pages
http://dx.doi.org/10.1155/2016/1615735
Review Article

Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

Received 9 June 2016; Revised 19 September 2016; Accepted 22 September 2016

Academic Editor: Małgorzata Kotula-Balak

Copyright © 2016 Giuseppina T. Russo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Hernlund, A. Svedbom, M. Ivergård et al., “Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA),” Archives of Osteoporosis, vol. 8, no. 1-2, article no. 136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. K. Wells, “Sexual dimorphism of body composition,” Best Practice & Research: Clinical Endocrinology & Metabolism, vol. 21, no. 3, pp. 415–430, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. E. M. Lewiecki, N. B. Watts, M. R. McClung et al., “Official positions of the International Society for Clinical Densitometry,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 8, pp. 3651–3655, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. World Health Organization, “Assessment of fracture risk an its application to screening for postmenopausal osteoporosis: report of a WHO study group,” World Health Organization Technical Report Series, vol. 843, pp. 1–129, 1994. View at Google Scholar
  5. O. Ström, F. Borgström, J. A. Kanis et al., “Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA),” Archives of Osteoporos, vol. 6, pp. 59–155, 2011. View at Google Scholar
  6. G. T. Russo, G. Baggio, M. C. Rossi, and A. Kautzky-Willer, “Type 2 diabetes and cardiovascular risk in women,” International Journal of Endocrinology, vol. 2015, Article ID 832484, 2 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. G. T. Russo, A. Giandalia, E. L. Romeo et al., “Lipid and non-lipid cardiovascular risk factors in postmenopausal type 2 diabetic women with and without coronary heart disease,” Journal of Endocrinological Investigation, vol. 37, no. 3, pp. 261–268, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. P. L. A. Van Daele, R. P. Stolk, H. Burger et al., “Bone density in non-insulin-dependent diabetes mellitus: The Rotterdam Study,” Annals of Internal Medicine, vol. 122, no. 6, pp. 409–414, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. I. I. De Liefde, M. Van der Klift, C. E. D. H. de Laet, P. L. A. Van Daele, A. Hofman, and H. A. P. Pols, “Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study,” Osteoporosis International, vol. 16, no. 12, pp. 1713–1720, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. E. S. Strotmeyer, J. A. Cauley, A. V. Schwartz et al., “Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study,” Archives of Internal Medicine, vol. 165, no. 14, pp. 1612–1617, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. W.-P. Koh, R. Wang, L.-W. Ang, D. Heng, J.-M. Yuan, and M. C. Yu, “Diabetes and risk of hip fracture in the Singapore Chinese Health Study,” Diabetes Care, vol. 33, no. 8, pp. 1766–1770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Vestergaard, L. Rejnmark, and L. Mosekilde, “Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes,” Calcified Tissue International, vol. 84, no. 1, pp. 45–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. L. Lipscombe, S. A. Jamal, G. L. Booth, and G. A. Hawker, “The risk of hip fractures in older individuals with diabetes: A Population-Based Study,” Diabetes Care, vol. 30, no. 4, pp. 835–841, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. K. K. Nicodemus and A. R. Folsom, “Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women,” Diabetes Care, vol. 24, no. 7, pp. 1192–1197, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. A. V. Schwartz, D. E. Sellmeyer, K. E. Ensrud et al., “Older women with diabetes have an increased risk of fracture: a prospective study,” The Journal of Clinical Endocrinology & Metabolism, vol. 86, no. 1, pp. 32–38, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. D. E. Bonds, J. C. Larson, A. V. Schwartz et al., “Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study,” Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 9, pp. 3404–3410, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Janghorbani, D. Feskanich, W. C. Willett, and F. Hu, “Prospective study of diabetes and risk of hip fracture: the nurses' health study,” Diabetes Care, vol. 29, no. 7, pp. 1573–1578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Basile, A. Crucitti, M. D. Cucinotta et al., “Impact of diabetes on cognitive impairment and disability in elderly hospitalized patients with heart failure,” Geriatrics and Gerontology International, vol. 13, no. 4, pp. 1035–1042, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. T. Russo, A. Giandalia, E. L. Romeo et al., “Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin,” Journal of Endocrinological Investigation, vol. 39, no. 3, pp. 305–314, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Altavilla, A. Saitta, D. Cucinotta et al., “Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse,” Diabetes, vol. 50, no. 3, pp. 667–674, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. K. M. Thrailkill, C. K. Lumpkin Jr., R. C. Bunn, S. F. Kemp, and J. L. Fowlkes, “Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues,” American Journal of Physiology—Endocrinology and Metabolism, vol. 289, no. 5, pp. E735–E745, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Yamaguchi and T. Sugimoto, “Bone metabolism and fracture risk in type 2 diabetes mellitus,” Endocrine Journal, vol. 58, no. 8, pp. 613–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Yang, X. Hu, Q. Zhang, H. Cao, J. Wang, and B. Liu, “Homocysteine level and risk of fracture: a meta-analysis and systematic review,” Bone, vol. 51, no. 3, pp. 376–382, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. G. T. Russo, A. Di Benedetto, E. Alessi et al., “Menopause modulates homocysteine levels in diabetic and non-diabetic women,” Journal of Endocrinological Investigation, vol. 31, no. 6, pp. 546–551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Qin, Y. Huo, D. Xie, F. Hou, X. Xu, and X. Wang, “Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials,” Clinical Nutrition, vol. 32, no. 5, pp. 722–727, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. G. T. Russo, A. Di Benedetto, D. Magazzù et al., “Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: A Prospective Study,” Acta Diabetologica, vol. 48, no. 2, pp. 95–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Takagi, S. Kasayama, T. Yamamoto et al., “Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells,” Journal of Bone and Mineral Research, vol. 12, no. 3, pp. 439–446, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Viguet-Carrin, J. P. Roux, M. E. Arlot et al., “Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae,” Bone, vol. 39, no. 5, pp. 1073–1079, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. K.-H. Ding, Z.-Z. Wang, M. W. Hamrick et al., “Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss,” Biochemical and Biophysical Research Communications, vol. 340, no. 4, pp. 1091–1097, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Kanazawa, T. Yamaguchi, M. Yamamoto et al., “Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 45–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Ferron, E. Hinoi, G. Karsenty, and P. Ducy, “Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 13, pp. 5266–5270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Yu, Q. Tu, Q. Han et al., “Adiponectin regulates bone marrow mesenchymal stem cell niche through a unique signal transduction pathway: an approach for treating bone disease in diabetes,” Stem Cells, vol. 33, no. 1, pp. 240–252, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. G. E. Sroga, P.-C. Wu, and D. Vashishth, “Insulin-like growth factor 1, glycation and bone fragility: implications for fracture resistance of bone,” PLoS ONE, vol. 10, no. 1, Article ID e0117046, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Terada, M. Inaba, Y. Yano et al., “Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells,” Bone, vol. 22, no. 1, pp. 17–23, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. A. D. McCarthy, S. B. Etcheverry, and A. M. Cortizo, “Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development,” Acta Diabetologica, vol. 38, no. 3, pp. 113–122, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Yano, and T. Sugimoto, “Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus,” Osteoporosis International, vol. 18, no. 12, pp. 1675–1681, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Morabito, G. T. Russo, A. Gaudio et al., “The ‘lively’ cytokines network in β-Thalassemia Major-related osteoporosis,” Bone, vol. 40, no. 6, pp. 1588–1594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Mitri, M. D. Muraru, and A. G. Pittas, “Vitamin D and type 2 diabetes: a systematic review,” European Journal of Clinical Nutrition, vol. 65, no. 9, pp. 1005–1015, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. G. Pittas, S. S. Harris, M. Eliades, P. Stark, and B. Dawson-Hughes, “Association between Serum Osteocalcin and Markers of Metabolic Phenotype,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 3, pp. 827–832, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. E. S. Strotmeyer, J. A. Cauley, A. V. Schwartz et al., “Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study,” Journal of Bone and Mineral Research, vol. 19, no. 7, pp. 1084–1091, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. J. C. Krakauer, M. J. McKenna, N. F. Buderer, D. Sudhaker Rao, F. W. Whitehouse, and A. Michael Parfitt, “Bone loss and bone turnover in diabetes,” Diabetes, vol. 44, no. 7, pp. 775–782, 1995. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Rakic, W. A. Davis, S. A. P. Chubb, F. M. A. Islam, R. L. Prince, and T. M. E. Davis, “Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study,” Diabetologia, vol. 49, no. 5, pp. 863–871, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Yamamoto, T. Yamaguchi, K. Nawata, M. Yamauchi, and T. Sugimoto, “Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 4, pp. 1277–1284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Vestergaard, “Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis,” Osteoporosis International, vol. 18, no. 4, pp. 427–444, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Gorman, A. M. Chudyk, K. M. Madden, and M. C. Ashe, “Bone health and type 2 diabetes mellitus: a systematic review,” Physiotherapy Canada, vol. 63, no. 1, pp. 8–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. L. J. Melton, B. L. Riggs, C. L. Leibson et al., “A bone structural basis for fracture risk in diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, pp. 4804–4809, 2008. View at Google Scholar
  48. M. A. Petit, M. L. Paudel, B. C. Taylor et al., “Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study,” Journal of Bone and Mineral Research, vol. 25, no. 2, pp. 285–291, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Tao, J.-M. Liu, H.-Y. Zhao et al., “Differences between measurements of bone mineral densities by quantitative ultrasound and dual-energy X-ray absorptiometry in type 2 diabetic postmenopausal women,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 5, pp. 1670–1675, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Sosa, P. Saavedra, E. Jódar et al., “Bone mineral density and risk of fractures in aging, obese post-menopausal women with type 2 diabetes. The GIUMO Study,” Aging Clinical and Experimental Research, vol. 21, no. 1, pp. 27–32, 2009. View at Publisher · View at Google Scholar
  51. A. Catalano, N. Morabito, G. Di Vieste et al., “Phalangeal quantitative ultrasound and metabolic control in pre-menopausal women with Type 1 diabetes mellitus,” Journal of Endocrinological Investigation, vol. 36, no. 5, pp. 347–351, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Dhaliwal, D. Cibula, C. Ghosh, R. S. Weinstock, and A. M. Moses, “Bone quality assessment in type 2 diabetes mellitus,” Osteoporosis International, vol. 25, no. 7, pp. 1969–1973, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. P.-F. Shan, X.-P. Wu, H. Zhang et al., “Bone mineral density and its relationship with body mass index in postmenopausal women with type 2 diabetes mellitus in mainland China,” Journal of Bone and Mineral Metabolism, vol. 27, no. 2, pp. 190–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. D. M. Black, N. K. Arden, L. Palermo, J. Pearson, and S. R. Cummings, “Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures,” Journal of Bone and Mineral Research, vol. 14, no. 5, pp. 821–828, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Yamamoto, T. Yamaguchi, M. Yamauchi, H. Kaji, and T. Sugimoto, “Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications,” Journal of Bone and Mineral Research, vol. 24, no. 4, pp. 702–709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. A. Kanis, “Assessment of osteoporosis at the primary health-care level,” Tech. Rep., WHO Collaborating Centre for Metabolic Bone Disease, University of Sheffield, Sheffield, UK, 2012. View at Google Scholar
  57. J. A. Kanis, A. Oden, H. Johansson, F. Borgström, O. Ström, and E. McCloskey, “FRAX® and its applications to clinical practice,” Bone, vol. 44, no. 5, pp. 734–743, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. J. A. Kanis, A. Oden, O. Johnell et al., “The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women,” Osteoporosis International, vol. 18, no. 8, pp. 1033–1046, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. A. V. Schwartz, E. Vittinghoff, D. C. Bauer et al., “Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes,” JAMA, vol. 305, no. 21, pp. 2184–2192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. L. M. Giangregorio, W. D. Leslie, L. M. Lix et al., “FRAX underestimates fracture risk in patients with diabetes,” Journal of Bone and Mineral Research, vol. 27, no. 2, pp. 301–308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. H. P. Bhattoa, U. Onyeka, E. Kalina et al., “Bone metabolism and the 10-year probability of hip fracture and a major osteoporotic fracture using the country-specific FRAX algorithm in men over 50 years of age with type 2 diabetes mellitus: a case-control study,” Clinical Rheumatology, vol. 32, no. 8, pp. 1161–1167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. J. Choi, S. Y. Ock, and Y. S. Chung, “Trabecular Bone Score (TBS) and TBS-adjusted fracture risk assessment tool are potential supplementary tools for the discrimination of morphometric vertebral fractures in postmenopausal women with type 2 diabetes,” Journal of Clinical Densitometry, vol. 19, no. 4, pp. 507–514, 2016. View at Publisher · View at Google Scholar
  63. E. Barrett-Connor and T. L. Holbrook, “Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus,” Journal of the American Medical Association, vol. 268, no. 23, pp. 3333–3337, 1992. View at Publisher · View at Google Scholar · View at Scopus
  64. J.-L. Pérez-Castrillón, D. De Luis, J. C. Martín-Escudero, T. Asensio, R. Del Amo, and O. Izaola, “Non-insulin-dependent diabetes, bone mineral density, and cardiovascular risk factors,” Journal of Diabetes and Its Complications, vol. 18, no. 6, pp. 317–321, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Rasul, A. Ilhan, L. Wagner, A. Luger, and A. Kautzky-Willer, “Diabetic polyneuropathy relates to bone metabolism and markers of bone turnover in elderly patients with type 2 diabetes: greater effects in male patients,” Gender Medicine, vol. 9, no. 3, pp. 187–196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Isanne Schacter and W. D. Leslie, “Spine-hip thickness difference measured by dual-energy X-ray absorptiometry is associated with diabetes mellitus in women and men,” Journal of Clinical Densitometry, vol. 18, no. 4, pp. 512–518, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Epstein, G. Defeudis, S. Manfrini, N. Napoli, and P. Pozzilli, “Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition,” Osteoporosis International, vol. 27, no. 6, pp. 1931–1951, 2016. View at Publisher · View at Google Scholar
  68. C. Meier, A. V. Schwartz, A. Egger, and B. Lecka-Czernik, “Effects of diabetes drugs on the skeleton,” Bone, vol. 82, pp. 93–100, 2016. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Vallarino, A. Perez, G. Fusco et al., “Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights,” Clinical Drug Investigation, vol. 33, no. 9, pp. 621–631, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Monami, B. Cresci, A. Colombini et al., “Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study,” Diabetes Care, vol. 31, no. 2, pp. 199–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Cucinotta and G. T. Russo, “Biphasic insulin aspart in the treatment of type 2 diabetes mellitus,” Expert Opinion on Pharmacotherapy, vol. 10, no. 17, pp. 2905–2911, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. R. L. Kennedy, J. Henry, A. J. Chapman, R. Nayar, P. Grant, and A. D. Morris, “Accidents in patients with insulin-treated diabetes: increased risk of low-impact falls but not motor vehicle crashes—a prospective register-based study,” The Journal of Trauma, vol. 52, no. 4, pp. 660–666, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Sedlinsky, M. S. Molinuevo, A. M. Cortizo et al., “Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats,” European Journal of Pharmacology, vol. 668, no. 3, pp. 477–485, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. W. G. Jang, E. J. Kim, I.-H. Bae et al., “Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2,” Bone, vol. 48, no. 4, pp. 885–893, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. Q. G. Mai, Z. M. Zhang, S. Xu et al., “Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats,” Journal of Cellular Biochemistry, vol. 112, no. 10, pp. 2902–2909, 2011. View at Publisher · View at Google Scholar
  76. S. Kiechl, J. Wittmann, A. Giaccari et al., “Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus,” Nature Medicine, vol. 19, no. 3, pp. 358–363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Lasco, N. Morabito, G. Basile et al., “Denosumab inhibition of RANKL and insulin resistance in postmenopausal women with osteoporosis,” Calcified Tissue International, vol. 98, no. 2, pp. 123–128, 2016. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Vestergaard, L. Rejnmark, and L. Mosekilde, “Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk,” Diabetologia, vol. 48, no. 7, pp. 1292–1299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. I. Kanazawa, T. Yamaguchi, M. Yamamoto, and T. Sugimoto, “Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus,” Journal of Bone and Mineral Metabolism, vol. 28, no. 5, pp. 554–560, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. K. L. Lapane, S. Yang, M. J. Brown, R. Jawahar, C. Pagliasotti, and S. Rajpathak, “Sulfonylureas and risk of falls and fractures: a systematic review,” Drugs & Aging, vol. 30, no. 7, pp. 527–547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. L. J. Melton III, C. L. Leibson, S. J. Achenbach, T. M. Therneau, and S. Khosla, “Fracture risk in type 2 diabetes: update of a population-based study,” Journal of Bone and Mineral Research, vol. 23, no. 8, pp. 1334–1342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. G. T. Russo, C. B. Giorda, S. Cercone et al., “Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study,” PLoS ONE, vol. 9, no. 10, Article ID e109702, 2014. View at Publisher · View at Google Scholar · View at Scopus
  83. A. V. Schwartz, “TZDs and bone: a review of the recent clinical evidence,” PPAR Research, vol. 2008, Article ID 297893, 6 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. S. E. Kahn, S. M. Haffner, M. A. Heise et al., “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy,” New England Journal of Medicine, vol. 355, no. 23, pp. 2427–2443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. S. E. Kahn, B. Zinman, J. M. Lachin et al., “Diabetes Outcome Progression Trial (ADOPT) Study Group Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT),” Diabetes Care, vol. 31, no. 5, pp. 845–851, 2008. View at Publisher · View at Google Scholar
  86. “Takeda Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for type 2 diabetes mellitus,” Letter to Health Care Providers, 2007, http://www.fda.gov/medwatch/safety/2007/Actosmar0807.pdf.
  87. A. Grey, M. Bolland, G. Gamble et al., “The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 4, pp. 1305–1310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. Z. Berberoglu, A. Gursoy, N. Bayraktar, A. C. Yazici, N. B. Tutuncu, and N. G. Demirag, “Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women,” Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 9, pp. 3523–3530, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Glintborg, M. Andersen, C. Hagen, L. Heickendorff, and A. P. Hermann, “Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 5, pp. 1696–1701, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Lecka-Czernik, “Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis,” Current Osteoporosis Reports, vol. 8, no. 4, pp. 178–184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. T. P. van Staa, H. G. M. Leufkens, and C. Cooper, “The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis,” Osteoporosis International, vol. 13, no. 10, pp. 777–787, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Yaturu, B. Bryant, and S. K. Jain, “Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men,” Diabetes Care, vol. 30, no. 6, pp. 1574–1576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. G. T. Russo, A. M. Labate, A. Giandalia et al., “Twelve-month treatment with liraglutide ameliorates visceral adiposity index and common cardiovascular risk factors in type 2 diabetes outpatients,” Journal of Endocrinological Investigation, vol. 38, no. 1, pp. 81–89, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. C. Yamada, Y. Yamada, K. Tsukiyama et al., “The murine glucagon-like peptide-1 receptor is essential for control of bone resorption,” Endocrinology, vol. 149, no. 2, pp. 574–579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. M. C. Bunck, B. Eliasson, A. Cornér et al., “Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 374–377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. G. Mabilleau, A. Mieczkowska, and D. Chappard, “Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials,” Journal of Diabetes, vol. 6, no. 3, pp. 260–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. B. Su, H. Sheng, M. Zhang et al., “Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials,” Endocrine, vol. 48, no. 1, pp. 107–115, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. J. H. M. Driessen, H. A. W. van Onzenoort, R. M. A. Henry et al., “Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture,” Bone, vol. 68, pp. 124–130, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Monami, I. Dicembrini, A. Antenore, and E. Mannucci, “Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials,” Diabetes Care, vol. 34, no. 11, pp. 2474–2476, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. M. P. Gilbert and R. E. Pratley, “The impact of diabetes and diabetes medications on bone health,” Endocrine Reviews, vol. 36, no. 2, pp. 194–213, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. Ö. Ljunggren, J. Bolinder, L. Johansson et al., “Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin,” Diabetes, Obesity and Metabolism, vol. 14, no. 11, pp. 990–999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. D. E. Kohan, P. Fioretto, W. Tang, and J. F. List, “Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control,” Kidney International, vol. 85, no. 4, pp. 962–971, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. A. Ptaszynska, K. M. Johnsson, S. J. Parikh, T. W. A. de Bruin, A. M. Apanovitch, and J. F. List, “Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events,” Drug Safety, vol. 37, no. 10, pp. 815–829, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. European Medicines Agency, Summary of the Risk Management Plan (RMP) for Jardiance (Empagliflozin), 2014.
  105. N. B. Watts, J. P. Bilezikian, K. Usiskin et al., “Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 1, pp. 157–166, 2016. View at Publisher · View at Google Scholar · View at Scopus
  106. J. P. Bilezikian, N. B. Watts, K. Usiskin et al., “Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin,” Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 1, pp. 44–51, 2016. View at Publisher · View at Google Scholar · View at Scopus
  107. C. Becker, S. Crow, J. Toman et al., “Characteristics of elderly patients admitted to an urban tertiary care hospital with osteoporotic fractures: correlations with risk factors, fracture type, gender and ethnicity,” Osteoporosis International, vol. 17, no. 3, pp. 410–416, 2006. View at Publisher · View at Google Scholar · View at Scopus